Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4328MR)

This product GTTS-WQ4328MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4328MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5296MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ4041MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ9947MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ4957MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ3149MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ179MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ1040MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ683MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW